Roivant Sciences (NASDAQ:ROIV) Major Shareholder Sells $7,800,077.25 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 353,745 shares of Roivant Sciences stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.05, for a total transaction of $7,800,077.25. Following the transaction, the insider directly owned 34,132,463 shares in the company, valued at $752,620,809.15. The trade was a 1.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Thursday, December 11th, Vivek Ramaswamy sold 774,142 shares of Roivant Sciences stock. The shares were sold at an average price of $21.64, for a total transaction of $16,752,432.88.
• On Friday, December 12th, Vivek Ramaswamy sold 1,975,858 shares of Roivant Sciences stock. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68.
• On Monday, November 17th, Vivek Ramaswamy sold 539,650 shares of Roivant Sciences stock. The shares were sold at an average price of $20.51, for a total transaction of $11,068,221.50.
• On Friday, November 14th, Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock. The stock was sold at an average price of $20.33, for a total value of $20,892,531.10.
• On Thursday, November 13th, Vivek Ramaswamy sold 287,283 shares of Roivant Sciences stock. The stock was sold at an average price of $20.81, for a total value of $5,978,359.23.

Roivant Sciences Trading Down 1.0%

NASDAQ:ROIV opened at $22.70 on Thursday. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $23.47. The stock has a 50-day moving average price of $19.76 and a two-hundred day moving average price of $14.95. The stock has a market cap of $15.79 billion, a price-to-earnings ratio of -40.54 and a beta of 1.22.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of research reports. The Goldman Sachs Group increased their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday. Citigroup upped their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. raised their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.81.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Perceptive Advisors LLC bought a new position in Roivant Sciences in the second quarter valued at $37,546,000. Nuveen LLC bought a new stake in Roivant Sciences during the 1st quarter worth about $31,988,000. Marshall Wace LLP lifted its position in Roivant Sciences by 316.5% during the 3rd quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after buying an additional 3,022,851 shares in the last quarter. Orbimed Advisors LLC acquired a new position in shares of Roivant Sciences during the 2nd quarter worth about $31,324,000. Finally, Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after acquiring an additional 2,603,260 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.